English
 
 

About Decheng Capital

Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. Located in Shanghai and Silicon Valley, we are a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of healthcare industry as well as breakthroughs in life science research. With over $1 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

 

 

News

December 12, 2018
Checkmate Pharmaceuticals Announces CEO Transition and $22 Million Financing

October 30, 2018
Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer

August 8, 2018
Apexigen Raises $73 Million In Series B And Series C Financings

August 3, 2018
IMPACT Therapeutics Raises $30 Million In Series C Financing

July 30, 2018
Omniome Completes $60 Million Series B Financing To Advance Novel Genomic Sequencing Technology

July 17, 2018
Polares Raises $25M to Bring its 'Hemi-Replacement' Mitral Valve to the Clinic

October 1, 2018
VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Clinic

June 14, 2018
Mindstrong Health Announces $15M Series B Round Financing and Business Update

May 10, 2018
Lilly Announces Agreement To Acquire ARMO BioSciences

January 25, 2018
ARMO BioSciences Announces Pricing of Initial Public Offering

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.